Free Trial

ABIVAX Société Anonyme (ABVX) Expected to Announce Quarterly Earnings on Monday

ABIVAX Société Anonyme logo with Medical background

ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) is anticipated to release its earnings data before the market opens on Monday, June 2nd. Analysts expect ABIVAX Société Anonyme to post earnings of ($1.59) per share and revenue of $3.11 million for the quarter.

ABIVAX Société Anonyme Price Performance

ABIVAX Société Anonyme stock traded down $0.01 during trading hours on Wednesday, hitting $5.68. The stock had a trading volume of 290,200 shares, compared to its average volume of 140,806. The business's 50 day simple moving average is $6.32 and its 200-day simple moving average is $7.02. ABIVAX Société Anonyme has a one year low of $4.77 and a one year high of $14.71.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently added to or reduced their stakes in ABVX. Millennium Management LLC lifted its holdings in shares of ABIVAX Société Anonyme by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company's stock valued at $6,171,000 after purchasing an additional 56,235 shares in the last quarter. Woodline Partners LP lifted its holdings in shares of ABIVAX Société Anonyme by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company's stock valued at $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of ABIVAX Société Anonyme by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock valued at $63,000 after purchasing an additional 2,595 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of ABIVAX Société Anonyme by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Institutional investors and hedge funds own 47.91% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABVX. JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Wednesday, April 30th. Morgan Stanley reissued an "equal weight" rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th.

View Our Latest Stock Analysis on ABIVAX Société Anonyme

About ABIVAX Société Anonyme

(Get Free Report)

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

Recommended Stories

Should You Invest $1,000 in ABIVAX Société Anonyme Right Now?

Before you consider ABIVAX Société Anonyme, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.

While ABIVAX Société Anonyme currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines